Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A416YS | ISIN: US00901B3033 | Ticker-Symbol: HXB
Lang & Schwarz
30.08.25 | 13:04
0,073 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AIM IMMUNOTECH INC Chart 1 Jahr
5-Tage-Chart
AIM IMMUNOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0660,08030.08.

Aktuelle News zur AIM IMMUNOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.08.AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment3
15.08.AIM ImmunoTech GAAP EPS of -$3.683
15.08.AIM ImmunoTech Inc.: AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update156Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment...
► Artikel lesen
14.08.AIM ImmunoTech Inc. - 10-Q, Quarterly Report1
AIM IMMUNOTECH Aktie jetzt für 0€ handeln
13.08.Uncovering Potential: AIM ImmunoTech's Earnings Preview2
06.08.AIM ImmunoTech Inc.: AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)168There will be presentations on the latest positive progress from AIM's clinical program in pancreatic cancer, the positive therapeutic effects of AIM's drug Ampligen on multiple cancer types, and...
► Artikel lesen
04.08.AIM ImmunoTech Inc.: AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval147Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive...
► Artikel lesen
31.07.AIM ImmunoTech Inc.: AIM ImmunoTech Announces Closing of $8.0 Million Public Offering1
29.07.AIM ImmunoTech stock plunges after pricing $8 million public offering5
29.07.AIM ImmunoTech prices $8 million public offering at $4.00 per share4
29.07.Pre-market Movers: DURECT Corporation, Salarius Pharmaceuticals, ScanTech AI Systems, AIM ImmunoTech, Bakkt Holdings599OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green DURECT Corporation (DRRX) is up over 267% at $2.03. Salarius...
► Artikel lesen
29.07.AIM ImmunoTech announces pricing of $8 million public offering; shares down over 50%2
29.07.AIM ImmunoTech Inc.: AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering160OCALA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the "Company"), today announced the pricing of a public offering of an aggregate of 2,000,000 shares of its...
► Artikel lesen
28.07.Why Is Micro-Cap AIM ImmunoTech Stock Surging?2
28.07.AIM ImmunoTech Inc. - 8-K, Current Report3
28.07.AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic ...217OCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical...
► Artikel lesen
15.07.AIM ImmunoTech Inc. - S-8, Securities to be offered to employees in employee benefit plans2
15.07.AIM ImmunoTech Inc. - S-1/A, General form for registration of securities1
02.07.AIM ImmunoTech Inc.: AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies2
20.06.AIM ImmunoTech Inc. - 8-K, Current Report2
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2